140 related articles for article (PubMed ID: 35716662)
21. Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.
Kim JH; Pandit N; Yoo M; Park TH; Choi JU; Park CH; Jung KY; Lee BI
Sci Rep; 2023 Jul; 13(1):10805. PubMed ID: 37402749
[TBL] [Abstract][Full Text] [Related]
22. Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells.
Khan YM; Kirkham P; Barnes PJ; Adcock IM
PLoS One; 2014; 9(4):e95051. PubMed ID: 24759736
[TBL] [Abstract][Full Text] [Related]
23. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of coronavirus E protein interactions with human PALS1 PDZ domain.
Javorsky A; Humbert PO; Kvansakul M
Commun Biol; 2021 Jun; 4(1):724. PubMed ID: 34117354
[TBL] [Abstract][Full Text] [Related]
25. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
Wu X; Qi J; Bradner JE; Xiao G; Chen LF
J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
[TBL] [Abstract][Full Text] [Related]
26. A short sequence in the tail of SARS-CoV-2 envelope protein controls accessibility of its PDZ-binding motif to the cytoplasm.
Neitthoffer B; Alvarez F; Larrous F; Caillet-Saguy C; Etienne-Manneville S; Boëda B
J Biol Chem; 2024 Jan; 300(1):105575. PubMed ID: 38110034
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV2 envelope protein: non-synonymous mutations and its consequences.
Hassan SS; Choudhury PP; Roy B
Genomics; 2020 Nov; 112(6):3890-3892. PubMed ID: 32640274
[TBL] [Abstract][Full Text] [Related]
28. Small Structural Proteins E and M Render the SARS-CoV-2 Pseudovirus More Infectious and Reveal the Phenotype of Natural Viral Variants.
Wang HI; Chuang ZS; Kao YT; Lin YL; Liang JJ; Liao CC; Liao CL; Lai MMC; Yu CY
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445789
[TBL] [Abstract][Full Text] [Related]
29. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy.
Yang GJ; Wang W; Lei PM; Leung CH; Ma DL
Int J Biol Macromol; 2020 Dec; 164():3204-3220. PubMed ID: 32860796
[TBL] [Abstract][Full Text] [Related]
30. Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.
Crowe BL; Larue RC; Yuan C; Hess S; Kvaratskhelia M; Foster MP
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2086-91. PubMed ID: 26858406
[TBL] [Abstract][Full Text] [Related]
31. High resolution crystal structure of BRD4-BD1 in complex with a novel inhibitor precursor.
Ma X; Wang M; Wang F; Li J; Zhang Z; Zhu J; Liu B
Biochem Biophys Res Commun; 2024 Jan; 690():149284. PubMed ID: 38006801
[TBL] [Abstract][Full Text] [Related]
32. The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation.
Zhang M; Wang B; Urabe G; Huang Y; Plutzky J; Kent KC; Guo LW
Cell Signal; 2019 Sep; 61():20-29. PubMed ID: 31075399
[TBL] [Abstract][Full Text] [Related]
33. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
34. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
35. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.
Huang B; Yang XD; Zhou MM; Ozato K; Chen LF
Mol Cell Biol; 2009 Mar; 29(5):1375-87. PubMed ID: 19103749
[TBL] [Abstract][Full Text] [Related]
36. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein.
Yalcinkaya M; Liu W; Islam MN; Kotini AG; Gusarova GA; Fidler TP; Papapetrou EP; Bhattacharya J; Wang N; Tall AR
Sci Rep; 2021 Dec; 11(1):24432. PubMed ID: 34952919
[TBL] [Abstract][Full Text] [Related]
37. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.
Xia B; Shen X; He Y; Pan X; Liu FL; Wang Y; Yang F; Fang S; Wu Y; Duan Z; Zuo X; Xie Z; Jiang X; Xu L; Chi H; Li S; Meng Q; Zhou H; Zhou Y; Cheng X; Xin X; Jin L; Zhang HL; Yu DD; Li MH; Feng XL; Chen J; Jiang H; Xiao G; Zheng YT; Zhang LK; Shen J; Li J; Gao Z
Cell Res; 2021 Aug; 31(8):847-860. PubMed ID: 34112954
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation.
Barman S; Sahoo SS; Padhan J; Sudhamalla B
J Biomol Struct Dyn; 2023 Dec; 41(20):10569-10581. PubMed ID: 36524430
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins.
Malvezzi F; Stubbs CJ; Jowitt TA; Dale IL; Guo X; DeGnore JP; Degliesposti G; Skehel JM; Bannister AJ; McAlister MS
Commun Biol; 2021 Nov; 4(1):1273. PubMed ID: 34754068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
